Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
A. Piedra,A. Barba Joaquin,J. Mosquera Martinez, M. Fernandez Bruno,P. Cordeiro Gonzalez, I. G. Sullivan,M. Riudavets Melia,M. Aguado Sorolla,P. Gallardo Melo,B. Martin Cullell,J. Gavira,J. C. Tapia, A. Romano, F. Bosma,S. Sanchez Del Rio,J. Sanz Beltran,M. A. Molina Perez,J. Serra Lopez,M. R. Garcia Campelo,M. Majem Tarruella ANNALS OF ONCOLOGY(2022)
AI 理解论文
溯源树
样例